Vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) in endothelial cells and pericytes can be targeted to reduce angiogenesis and cell proliferation via blockage of tumor cells’ B-RAF and RAF1 of the mitogen-activated protein kinase (MAPK) pathway [7,8]. The gene discussed is RAF1; the disease is neoplasm.